NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 1 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $41 | -60.6% | 38,861 | -3.8% | 0.00% | – |
Q2 2023 | $104 | -41.9% | 40,390 | -8.4% | 0.00% | – |
Q1 2023 | $179 | -48.9% | 44,077 | -36.9% | 0.00% | – |
Q4 2022 | $350 | -99.9% | 69,904 | +59.3% | 0.00% | -100.0% |
Q3 2022 | $575,000 | +76.4% | 43,895 | +72.6% | 0.00% | – |
Q2 2022 | $326,000 | +10.5% | 25,436 | +31.3% | 0.00% | – |
Q1 2022 | $295,000 | -85.1% | 19,371 | -82.6% | 0.00% | – |
Q4 2021 | $1,974,000 | +190.7% | 111,520 | +245.7% | 0.00% | – |
Q3 2021 | $679,000 | +452.0% | 32,261 | +420.2% | 0.00% | – |
Q2 2021 | $123,000 | -84.1% | 6,202 | -76.7% | 0.00% | – |
Q1 2021 | $773,000 | +57.1% | 26,569 | +63.6% | 0.00% | – |
Q4 2020 | $492,000 | +21.8% | 16,238 | -36.1% | 0.00% | – |
Q3 2020 | $404,000 | -10.2% | 25,396 | +11.2% | 0.00% | – |
Q2 2020 | $450,000 | +63.0% | 22,830 | +2.0% | 0.00% | – |
Q1 2020 | $276,000 | -65.5% | 22,381 | -48.3% | 0.00% | – |
Q4 2019 | $800,000 | +99.5% | 43,314 | +49.8% | 0.00% | – |
Q3 2019 | $401,000 | -6.3% | 28,916 | -1.3% | 0.00% | – |
Q2 2019 | $428,000 | – | 29,293 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |